EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Fixed vs Weight-Based Dosing of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Patients With a Non-Neurologic Hemorrhage

Tyson Stokes iD, Christopher Johnson, Tyler Fish, Aimee Mishler

Journal of Pharmacy Practice · 2025

DOI: 10.1177/08971900251319378 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Pharmacy Practice, 2025. Verfasst von Tyson Stokes und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, St. Luke's Health System, ID, USA. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Blood Coagulation Factors, Hemorrhage, Body Weight. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is a growing body of evidence to support that utilizing fixed dose vs weight-based dosing of Four-Factor prothrombin complex concentrate (4F-PCC) for Factor Xa inhibitor (FXaI) reversal is safe and efficacious.

Objectives

The primary objective of this study was the rate of hemostatic efficacy of weight-based (50 units/kg) vs fixed dose (2000 units) 4F-PCC for FXaI reversal in patients presenting with a non-neurologic hemorrhage.

Methods

This was a multi-center, retrospective chart review from January 21, 2020, to January 21, 2022. Patients were included if they were greater than or equal to 18 years of age and received one dose of 4F-PCC for FXaI reversal for a non-neurologic bleed. Hemostatic efficacy for this study was defined as the absence of hemorrhagic progression confirmed with imaging, >2 g/dl decrease in Hgb within 6 hours of 4F-PCC administration, reports of further significant bleeding in chart note documentation within 48 hours and a maintained or increased anti-factor Xa level from baseline.

Results

Fifty-nine patients were included in this study (29 in the weight-based group and 30 in the fixed dose group). Rate of hemostatic efficacy was similar between fixed and weight-based dosing (93.3% vs 93.1% P = 1).

Conclusions

This study adds to current evidence suggesting that a fixed dose 4F-PCC is both safe and efficacious for FXaI reversal in non-neurologic bleeds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor Xa InhibitorsBlood Coagulation FactorsHemorrhageBody WeightHumansRetrospective StudiesMaleFemaleAgedMiddle AgedAged, 80 and overDose-Response Relationship, Drug

Stichwörter der Autor:innen

4F-PCCDOACfactor Xa inhibitorshemorrhagereversal

Substanzen

Factor Xa InhibitorsBlood Coagulation Factorsprothrombin complex concentrates

Autor:innen und Institutionen

  • Department of Pharmacy, St. Luke's Health System, ID, USA.

ORCID-Profile: Tyson Stokes

Zitieren

APA

Stokes, T., Johnson, C., Fish, T., & Mishler, A. (2025). Fixed vs Weight-Based Dosing of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Patients With a Non-Neurologic Hemorrhage. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900251319378

Vancouver

Stokes T, Johnson C, Fish T, Mishler A. Fixed vs Weight-Based Dosing of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Patients With a Non-Neurologic Hemorrhage. Journal of Pharmacy Practice. 2025. doi:10.1177/08971900251319378

BibTeX
@article{Stokes2025,
  author = {Stokes, Tyson and Johnson, Christopher and Fish, Tyler and Mishler, Aimee},
  title = {Fixed vs Weight-Based Dosing of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Patients With a Non-Neurologic Hemorrhage},
  journal = {Journal of Pharmacy Practice},
  year = {2025},
  doi = {10.1177/08971900251319378}
}
Kostenlos starten →